Injection Fraud Is a Federal Enforcement Priority: Charges, Defenses, and What Providers Need to Know
Injection Fraud Is Drawing Aggressive Federal Enforcement in 2025 and 2026
Federal prosecutors are targeting medical injection fraud with increasing intensity. Facet joint injections, nerve blocks, trigger point injections, Botox injections, and other injectable therapies billed to Medicare and Medicaid are under direct scrutiny from DOJ's Health Care Fraud Unit, HHS-OIG, and CMS Program Integrity.
The DOJ Fraud Section's 2025 Year in Review specifically highlighted injection billing as an enforcement target. DOJ's Data Analytics Team identified billing anomalies at a California facility that billed Medicare for Botox injections to treat chronic migraines. That investigation led to a federal indictment in October 2025.
In December 2025, a federal grand jury in the Central District of California returned a superseding indictment charging a physician with submitting over $45 million in false Medicare claims for Botox injections that were medically unnecessary or never provided. The indictment alleged that claims were submitted on dates when the physician was traveling internationally, when the beneficiary was in federal prison, and when the clinic was closed. The physician also faces obstruction charges for allegedly submitting falsified medical records in response to a grand jury subpoena.
HHS-OIG has also audited facet joint injection billing around the country. HHS-OIG found that Medicare improperly paid an estimated $30 million for spinal facet joint interventions in a single audit period. A separate OIG audit found that approximately 22.6 percent of Medicare payments for facet joint injections during a rolling 12-month period did not meet Medicare coverage criteria. These audits feed directly into the investigative pipeline that leads to DOJ criminal referrals.
DOJ's newly announced Health Care Fraud Data Fusion Center now uses AI-driven analytics to identify injection billing outliers across every federal healthcare program. That capability makes injection fraud an area of heightened enforcement risk for every provider who bills Medicare or Medicaid for injectable therapies.
Types of Injection Fraud Cases That Draw Federal Prosecution
Federal injection fraud investigations cover a broad range of injectable therapies and billing practices. The common thread across all of these investigations and cases is high reimbursement rates, combined with billing patterns that deviate from statistical norms or comparable peer groups of providers.
Facet Joint Injections and Spinal Nerve Blocks
Facet joint injections and medial branch nerve blocks are among the most commonly targeted injection procedures in federal healthcare fraud cases. Medicare reimburses these procedures at high rates. As a result, high-volume billing for these procedures can be extremely profitable for providers. That reimbursement structure creates a built-in incentive for suspicions of overutilization.
Medicare Administrative Contractors have established Local Coverage Determinations that limit reimbursement to a maximum of five facet joint injection sessions per spinal region during a rolling 12-month period. Providers who exceed these limitations are flagged. CMS also requires that providers document the clinical indications for the procedures, including a history of at least three months of moderate to severe pain with functional impairment, before facet joint injections are covered or deemed medically necessary.
Federal prosecutors build facet joint fraud cases around three primary theories. First, that the injections were not medically necessary. Second, that the provider upcoded superficial injections as more complex spinal procedures. Third, that the provider billed for injections that were never performed. Each theory carries independent criminal exposure.
Trigger Point and Tendon Origin Injections
Trigger point injections are also a recurring target of federal enforcement. Government investigations in this area focus on providers who administer high volumes of superficial injections and then bill them under higher-reimbursement codes for procedures, such as tendon origin injections or nerve blocks. The underlying theory of investigation is the same: billing for medical services that were medically unnecessary or not provided.
Botox and Botulinum Toxin Injections
Medicare covers botulinum toxin injections for specific medical conditions, including chronic migraines, spasticity, and cervical dystonia. It does not cover Botox for cosmetic purposes. The gap between medical and cosmetic indications creates a fraud theory for law-enforcement investigations: providers who bill Medicare for cosmetic injections by fabricating clinical diagnoses in the beneficiary's medical record.
The December 2025 indictment in the Central District of California charged a physician with billing Medicare $45 million for Botox injections by fabricating diagnoses of chronic migraines. That case was initiated by DOJ's Data Analytics Team. This case represents a stark example of how the government will pursue injection fraud cases in 2026.
Epidural Steroid Injections
HHS-OIG has conducted national audits of epidural steroid injection billing. OIG found that 10 Medicare Administrative Contractors had established coverage limitations for epidural steroid injection sessions. In a two-year audit period, OIG identified over 80,000 sessions totaling $13.8 million that exceeded those coverage limitations. Providers who consistently exceed MAC-specific frequency limits face both administrative recoupment and criminal referral.
Injection Fraud Combined with Opioid Prescribing
Federal prosecutors have linked injection fraud to opioid diversion in several high-profile cases. In these cases, patients receive opioid prescriptions in exchange for submitting to medically unnecessary injections. The injections generate significant Medicare revenue for the provider and exposes medical professionals to a combination of charges involving both healthcare fraud and controlled substances violations under Title 21, which dramatically increases a provider's sentencing exposure.
"The defendant, Michael Kestner, found out about an injection that could be billed a lot and paid well. And they turned some patients into human pin cushions."
— Federal Prosecutor James V. Hayes, Opening Statement, United States v. Kestner, M.D. Tenn. (2024)Billing Patterns That Trigger Federal Injection Fraud Investigations
Key Federal Charges in an Injection Fraud Case
Federal injection fraud indictments typically involve multiple charges across distinct legal theories. Each count carries its own statutory maximum. Sentencing exposure compounds rapidly.
Physicians who order or perform medically unnecessary injections face criminal exposure regardless of whether they personally submitted the claims. The government regularly charges ordering and performing physicians under conspiracy and aiding and abetting theories. A physician who signs orders or performs procedures knowing the claims are false or medically unsupported provides the factual basis for federal charges.
Key Defenses in a Federal Injection Fraud Case
Federal injection fraud cases are defensible. These prosecutions often involve clinical judgment calls and complex billing rules. These areas create genuine ambiguity and opportunities for strategic and effective defense arguments.
Medical Necessity and Clinical Judgment
The central defense in most injection fraud cases is medical necessity. Medicare billing requirements for facet joint injections, epidural steroid injections, and trigger point injections involve clinical assessments that are inherently subjective. Physicians exercise judgment about pain severity, functional impairment, and treatment response. That judgment should be entitled to deference and not be second guessed by law enforcement.
Experienced defense counsel retains pain management specialists and other clinical experts to demonstrate that the injections at issue were clinically indicated based on the patient's documented symptoms and examination findings at the time of treatment. The government must prove that the physician knew the services were not medically necessary (i.e., submitted as part of a scheme to defraud). Where a provider exercises his or her clinical, medical judgment in good faith, the government cannot meet that standard.
Lack of Willfulness and Specific Intent
Federal healthcare fraud under 18 U.S.C. § 1347 requires proof that the defendant knowingly and willfully executed a scheme to defraud. Billing errors are not crimes. Documentation failures are not crimes. A physician who believes in good faith that the injections are helping patients retains a substantial defense on wrongful intent, even if the billing is later found to be non-compliant with Medicare rules and regulations.
Proving wrongful intent is a high burden for the government. The government must prove beyond a reasonable doubt that the defendant acted with knowledge that the billing was false or fraudulent. Mere negligence, even substantial negligence, does not satisfy the willfulness element. The defense of many a healthcare fraud case turns on undercutting the government's anticipated proof of wrongful intent by a medical professional.
Challenging the Government's Data Analytics and Outlier Theory
DOJ's Data Analytics Team and HHS-OIG use claims data to identify billing outliers. Being a statistical outlier often triggers an investigation, especially in jurisdictions where DOJ's Strike Forces operate. But there is an important caveat: a billing outlier does not by itself prove fraud. Many reasons may exist why a provider is a legitimate outlier for any given service.
To show that a provider is a legitimate outlier, defense counsel challenges the government's benchmark populations, comparison groups, and the clinical characteristics of the defendant's patient population. A pain management practice that specializes in complex spinal conditions will naturally bill more injection procedures than a general practice. A practice in a geographic area with a higher concentration of elderly or disabled patients will have higher utilization rates. These are legitimate clinical explanations for statistical deviations. An experienced healthcare fraud defense attorney identifies the weaknesses in the government's data analysis and leverages for the provider's defense any underlying errors.
Challenging LCD Compliance Theories
Local Coverage Determinations establish billing rules that vary by Medicare Administrative Contractor. LCDs are not statutes. They are administrative guidelines. Violations of LCD frequency limitations can support recoupment. Violations of these LCDs do not automatically establish criminal fraud. Oftentimes, a technical violation of an LCD comes nowhere close to proof of fraudulent intent.
Defense counsel challenges the government's interpretation of LCD requirements or reliance on superseded LCDs. The defense strategy is to show that the provider made good-faith efforts to comply with applicable coverage rules. Where LCDs are ambiguous, the ambiguity favors the provider and undercuts a conclusion of criminal intent.
Disputing Upcoding Allegations
Injection upcoding cases depend on the government's proof of the procedures actually performed. The government seeks to find this proof through either EMR records, the statements of office workers or interviews with the beneficiaries themselves. Beyond finding holes in this proof, defense counsel retains medical coding experts and clinical specialists to demonstrate that the billed procedure codes accurately reflected the services provided. CPT code selection for injection procedures involves clinical distinctions that are not always clear-cut. Where the coding is defensible, the fraud theory against a provider fails.
Safe Harbor Analysis for Referral Arrangements
Where the government alleges kickbacks in connection with injection referrals, defense counsel analyzes each arrangement against the OIG Safe Harbor Regulations. The personal services safe harbor, the employee safe harbor, and the fair market value safe harbor can each provide protection for bona fide compensation arrangements. Experienced defense counsel retains fair market value experts to support the legitimacy of any challenged payment.
How DOJ Builds an Injection Fraud Case
| Investigative Stage | Government Actions | What It Means for Providers |
|---|---|---|
| Data Analytics Identification | CMS and DOJ's Data Fusion Center flag the provider as a billing outlier for injection volume, frequency, or coding patterns. | The provider may not know an investigation has begun. The first indication may be a UPIC audit or prepayment review notice. |
| UPIC Audit or Prepayment Review | A Unified Program Integrity Contractor requests medical records for specific claims. CMS may impose prepayment review of future claims. | This is a critical early-warning sign. Providers should retain defense counsel immediately. Responses to a UPIC audit may feed a parallel civil fraud or criminal investigation. |
| Grand Jury Investigation & Search Warrants | DOJ issues grand jury subpoenas for billing records, clinical documentation like EMRs, sales invoices, and financial records. DOJ also conducts search warrants, not only for electronic communications but also at a provider's business location. | Grand jury subpoenas confirm an active criminal investigation. Providers must retain federal criminal defense counsel before producing any documents. Search warrants for electronic communications are done covertly (or without notice to the provider). |
| Witness Interviews and Cooperators | FBI and HHS-OIG agents interview current and former employees, patients or beneficiaries, and business associates. The government recruits cooperating witnesses. | Employees may be cooperating without the provider's knowledge. Agent contact with staff is a serious indicator of an advanced criminal investigation. |
| Qui Tam Whistleblower Complaint | A current or former employee files a sealed False Claims Act complaint. DOJ investigates under seal before deciding to intervene. | The provider will not know about a sealed qui tam complaint. Unexplained departures by billing staff or unusual audit requests may indicate a whistleblower has come forward. |
| Indictment or Civil Complaint | A grand jury returns an indictment, or DOJ files a civil FCA complaint. The government may also seek asset seizure and forfeiture. | The government has decided to bring charges. Defense counsel must be prepared to challenge the indictment, negotiate bond, and protect assets. |
Frequently Asked Questions
What experience does Armstrong & Bradylyons PLLC bring to an injection fraud defense?
Scott Armstrong is a former Assistant Chief at DOJ's Fraud Section who has tried sixteen complex federal cases in federal courts around the country. At DOJ, he served as lead counsel in healthcare fraud cases totaling over $600 million in false claims to federal healthcare programs. He served as co-lead trial counsel in a federal jury trial against a physician charged with over $1.5 million in medically unnecessary facet injections in the Southern District of Texas. He also served as lead counsel in DOJ's most recent federal healthcare fraud case in the District of Columbia involving a physician who billed over $12 million for injection procedures to Medicare beneficiaries.
Drew Bradylyons is a former Assistant Chief at DOJ's Fraud Section who supervised the Healthcare Fraud Unit's South Florida Strike Force. He investigated and supervised cases involving more than $1 billion in fraudulent claims to Medicare, Medicaid, and TRICARE. He later served as Chief of the Financial Crimes and Public Corruption Unit at the U.S. Attorney's Office for the Eastern District of Virginia.
Together with Special Counsel Andrea Savdie, the firm's attorneys have over 25 years of combined DOJ experience, participated in 25 federal jury trials, and tried 17 healthcare fraud cases involving over $2.8 billion in alleged false claims.
What generally leads to DOJ opening an investigation of a pain-management physician?
DOJ's Health Care Fraud Data Fusion Center and HHS-OIG use claims-data analytics to identify billing outliers. Pain management providers are flagged when their injection volume, frequency, or coding patterns deviate significantly from statistical peers in the same specialty and geographic area. Exceeding Local Coverage Determination frequency limits for facet joint injections or epidural steroid injections is a primary red flag.
The government also investigates providers who routinely bill anesthesia services alongside injection procedures that LCDs classify as rarely requiring sedation. A UPIC audit or prepayment review notice is frequently the first visible sign that CMS has flagged a provider. Providers who receive these administrative notices should treat them as a potential precursor to criminal investigation.
What is upcoding in an injection fraud case?
Upcoding means billing a higher-reimbursement procedure code than the service actually performed. In injection cases, the government alleges that providers administered superficial trigger point injections but billed them as facet joint injections, nerve blocks, or tendon origin injections under higher-paying CPT codes.
The defense challenges this characterization through extensive medical-file review, interviews with a provider's staff, and testimony from medical coding experts about what procedure was actually performed. CPT code selection involves clinical distinctions that are not always clear-cut. That ambiguity is relevant to both the fraud element and the intent element under 18 U.S.C. section 1347. Billing errors and coding disagreements are not crimes.
How does DOJ use data analytics to identify injection fraud?
DOJ's Health Care Fraud Data Fusion Center combines CMS billing data with HHS-OIG investigative data and AI-driven analytics to identify billing outliers. For injection providers, the system flags high per-patient injection volumes, billing on dates when the facility was closed, claims for beneficiaries who were hospitalized or incarcerated, and injection coding that deviates from specialty norms. These analytics are investigative tools. The underlying outlier reports are not necessarily proof of fraud.
Scott Armstrong and Drew Bradylyons built healthcare fraud cases using these same data-analysis tools at DOJ's Fraud Section. They understand the limitations of statistical outlier analysis and use that knowledge to challenge the government's methodology, benchmark populations, and comparison groups.
What is the role of a qui tam whistleblower in an injection fraud investigation?
A qui tam lawsuit is a civil action filed under the False Claims Act by a whistleblower. It is typically filed by a current or former employee. It is filed under seal, served on DOJ, and investigated before the government decides whether to intervene. The provider does not know about a sealed complaint until the government intervenes or the seal is lifted.
A qui tam complaint frequently triggers a parallel criminal investigation. That parallel track is dangerous. Statements made in civil depositions or written responses can be used by federal prosecutors in a criminal proceeding. Drew Bradylyons served as Assistant Chief supervising the Healthcare Fraud Unit's Florida Strike Force, where qui tam complaints regularly initiated criminal investigations. He understands how these cases move from civil to criminal and defends clients with that risk in view from day one.
How does the government prove fraudulent intent in a healthcare fraud case involving injections?
Federal prosecutors rarely have direct evidence of intent. DOJ prosecutors instead prove fraudulent intent through circumstantial evidence. In injection fraud prosecutions, that evidence includes billing volume far exceeding statistical peers, clinical documentation that appears templated or identical across patients, billing for injections on dates when the provider or patient was unavailable, the absence of individualized clinical assessments, and testimony from office workers or patients.
The government also relies on compensation structures tied to injection volume and the provider's failure to follow LCD frequency limits despite notice. The legal standard under 18 U.S.C. section 1347 requires proof of knowing and willful conduct. At DOJ's Fraud Section, Scott Armstrong tried healthcare fraud cases involving millions upon millions of dollars in false claims in federal courts around the country. Scott Armstrong and Drew Bradylyons know exactly how federal prosecutors construct intent arguments from circumstantial evidence and how to dismantle them at trial.
Does the government charge both healthcare fraud and Anti-Kickback Statute violations in the same case?
Yes. Federal prosecutors routinely charge healthcare fraud under 18 U.S.C. section 1347 and Anti-Kickback Statute violations under 42 U.S.C. section 1320a-7b in the same indictment. The healthcare fraud charges target the submission of false claims for medically unnecessary injections. The AKS charges target payment arrangements that induced patient referrals for those procedures. These are distinct legal theories with independent elements.
The AKS "one purpose" test means that if even one purpose of a payment was to induce referrals, the statute is violated regardless of other legitimate purposes. Each AKS violation carries up to 10 years of imprisonment. The government also uses AKS violations to establish that the resulting claims are false under the False Claims Act, creating parallel civil exposure with treble damages. Defense counsel must address both theories simultaneously. Concessions on one theory strengthen the government's case on the other. Scott Armstrong and Drew Bradylyons led and tried the nation's highest-profile AKS cases and investigations for years as leaders in the Healthcare Fraud Unit of DOJ's Fraud Section.
What is the strongest evidence to challenge the government's theory of fraudulent intent?
Clinical documentation created at the time of treatment is the most powerful category of defense evidence. Individualized patient assessments, documented examination findings, treatment plans tied to specific diagnoses, and notes reflecting clinical decision-making all demonstrate that a physician exercised professional judgment, not a billing scheme.
Beyond documentation, defense counsel identifies favorable testimony from office employees, compliance program records, evidence of legal or billing consultation, continuing medical education on applicable coding rules, and expert testimony from pain management specialists. The government's case depends on proving that the defendant knew the billing was fraudulent. Contemporaneous evidence of good-faith clinical practice directly negates that element. Billing errors and negligence are not crimes under federal healthcare fraud statutes. Based on their senior-level experience at the Healthcare Fraud Unit of DOJ's Fraud Section, Scott Armstrong and Drew Bradylyons know where to identify this information and use it for maximum advantage on behalf of providers.
What role does CMS play in a civil fraud or criminal healthcare fraud investigation?
CMS plays a critical upstream role in federal healthcare fraud enforcement. CMS Program Integrity uses data analytics to identify billing outliers across Medicare and Medicaid. When CMS flags a provider, it can impose prepayment review, initiate a UPIC audit, suspend Medicare payments, or revoke billing privileges. CMS also refers cases, and documents it has collected from providers, to HHS-OIG and DOJ for civil and criminal investigation.
CMS administrative actions often run in parallel with DOJ criminal investigations. A parallel investigation can be dangerous for a provider. A provider who responds to a CMS audit without criminal defense counsel may make statements or produce documents that federal prosecutors later use in a criminal case. Scott Armstrong and Drew Bradylyons navigated this parallel-proceeding dynamic for years at DOJ's Fraud Section and the U.S. Attorney's Office for the Eastern District of Virginia. They defend clients with the ever-present risk of criminal referral in view from the outset.
What specific procedure and drug codes are commonly investigated in federal injection fraud cases?
Federal injection fraud investigations focus on two categories of billing codes: CPT procedure codes for the injection itself and HCPCS J codes for the drug administered. The procedure codes that draw the most scrutiny include CPT 64490 through 64495 for paravertebral facet joint injections, CPT 64479 through 64484 for transforaminal epidural steroid injections, CPT 20552 and 20553 for trigger point injections, and CPT 64633 through 64636 for radiofrequency ablation of facet joint nerves.
On the drug side, the J codes most frequently at issue include J3301 for triamcinolone acetonide (Kenalog), J1030 for methylprednisolone acetate (Depo-Medrol), J1100 for dexamethasone, J0702 for betamethasone, and J0585 for onabotulinumtoxinA (Botox). The government's upcoding theory typically alleges that a provider billed facet joint injection codes for services that were actually superficial trigger point injections. Because facet joint codes reimburse at significantly higher rates, the billing differential is substantial. Local Coverage Determinations set frequency limits and documentation requirements for each code. CMS has reported that the improper payment rate for facet joint injection claims has historically hovered near 50 percent.
As a leading trial attorney in the Healthcare Fraud Unit of DOJ's Fraud Section, Scott Armstrong investigated and tried federal cases involving nearly $15 million in claims under these codes. He now leverages that experience to defend providers around the country facing investigation and charges involving healthcare fraud for injection services.
Where does Armstrong & Bradylyons PLLC defend injection fraud cases?
Based in Washington, D.C., Armstrong & Bradylyons PLLC defends individuals in federal healthcare fraud investigations and prosecutions nationwide. The firm is set up to practice in every federal district court in the country, just like Scott Armstrong and Drew Bradylyons practiced in the Healthcare Fraud Unit of DOJ's Fraud Section.
DOJ's Health Care Fraud Strike Force operates in the Southern District of Florida, the Eastern District of Michigan, the Southern District of Texas, the Central District of California, the District of Massachusetts, the Northern District of Illinois, and additional federal districts. Healthcare fraud prosecutions also originate from U.S. Attorney's Offices beyond the Strike Force footprint. Scott Armstrong has tried sixteen complex federal cases in courts around the country, including nine healthcare fraud trials. Drew Bradylyons also tried cases at DOJ's Fraud Section, supervised the Healthcare Fraud Unit's busiest docket in the Southern District of Florida, and supervised investigations and cases at the U.S. Attorney's Office for the Eastern District of Virginia. The firm represents clients in every jurisdiction where DOJ brings healthcare fraud and Anti-Kickback Statute cases.
Facing a Federal Injection Fraud Investigation?
Armstrong & Bradylyons PLLC defends pain management physicians, clinic owners, and healthcare executives in federal injection fraud investigations nationwide. As a former Assistant Chief from DOJ's Fraud Section, Scott Armstrong defends medical professionals and healthcare executives in federal investigations involving healthcare fraud and violations of the Anti-Kickback Statute. As the former Assistant Chief of the Fraud Section's Miami Strike Force, Drew Bradylyons similarly defends individuals in healthcare fraud investigations. Together, the firm provides a trial-ready defense in complex healthcare fraud investigations.
